On 5–6 May, Basel buzzed with biotech brilliance as Swiss Biotech Days 2025 united over 3,000 innovators and investors from across theglobe. As a Swiss-headquartered CRO and proud member of the Swiss Biotech Association, Accelsiors was thrilled to dive into this dynamic event, now a cornerstone of the global biotech calendar.   At our booth,...

This year, Accelsiors had the unique opportunity to participate in the Festival of Biologics USA, held at the San Diego Convention Center on April 23–24. With over 1,500 participants and exhibitors from around the world, the Festival was an inspiring experience, offering opportunities for growth, raising Accelsiors’ visibility, and establishing many valuable new connections. The...

The Role of Biomarkers in Accelerating Drug Development Imagine developing a new drug for Alzheimer’s disease (AD)—only to discover halfway through clinical trials that many participants didn’t actually have the (right) disease pathology. This costly mistake is exactly why biomarkers are reshaping neurodegenerative disease drug development.  Biomarkers in clinical trials help researchers:  Identify the right...

Are you ready for the next big shift in biosimilar development?  The biosimilar landscape is evolving at lightning speed, driven by groundbreaking regulatory updates from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). The EMA’s 2025 reflection paper introduces a tailored clinical approach that promises to streamline biosimilar development, while...

The recent American Society of Clinical Oncology (ASCO) conference served as a platform for Accelsiors to showcase our expertise, forge valuable connections, and reinforce our commitment to advancing cancer care and saving lives. The conference also provided opportunities for us to share our latest technological achievements and demonstrate our commitment to staying at the forefront...

We are happy to announce that the first two patients have been successfully randomized in the Phase 2 portion of the clinical trial evaluating golexanolone for the treatment of cognitive symptoms in Primary Biliary Cholangitis (PBC). This randomized, double-blind, placebo-controlled study aims to assess the efficacy of golexanolone in improving cognitive function, fatigue, and daytime...